[{"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-001", "question": "A 68-year-old man with a history of severe COPD (FEV1 35% predicted) and chronic hypercapnia (baseline PaCO2 55 mmHg) presents with acute-on-chronic hypercapnic respiratory failure requiring non-invasive ventilation. After 48 hours of improvement, his arterial blood gas shows pH 7.36, PaCO2 48 mmHg, PaO2 85 mmHg on 2 L/min nasal cannula. He is alert and comfortable. The next most appropriate step in management is:", "options": ["Gradually wean and discontinue supplemental oxygen to target a PaO2 of 55-60 mmHg", "Continue current oxygen therapy and plan for discharge home with home oxygen", "Increase oxygen flow to achieve a PaO2 > 88 mmHg", "Obtain a venous blood gas to confirm the arterial values", "Initiate acetazolamide 250 mg twice daily to accelerate renal compensation"], "answer": "A", "answer_index": 0, "explanation": "In patients with chronic hypercapnia, the hypoxic drive is a primary respiratory stimulus. Over-oxygenation can suppress this drive, leading to worsening hypercapnia and acidosis. The target PaO2 is 55-60 mmHg or SpO2 88-92%, which provides adequate oxygenation while minimizing the risk of CO2 retention. Increasing oxygen (C) is dangerous, and acetazolamide (E) is not indicated in acute-on-chronic respiratory failure as it can worsen acidosis by inhibiting compensatory metabolic alkalosis.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "This patient has severe COPD with chronic hypercapnia (baseline PaCO2 55 mmHg). He is currently recovering from an episode of acute respiratory failure and has been stabilized.\n\nHis current arterial blood gas (ABG) on 2 L/min nasal cannula shows:\n*   pH 7.36 (Normal, slightly on the acidemic side of 7.40)\n*   PaCO2 48 mmHg (Improved, actually lower than his baseline of 55 mmHg)\n*   PaO2 85 mmHg (Hyperoxemia in the context of COPD)\n\nAnalysis:\n1.  Oxygenation: In patients with chronic hypercapnia (CO2 retainers), the target oxygen saturation is typically 88–92%, which corresponds roughly to a PaO2 of 60–70 mmHg. A PaO2 of 85 mmHg indicates excessive oxygen supplementation. While the \"hypoxic drive\" theory is an oversimplification, hyperoxia can worsen hypercapnia due to the Haldane effect (deoxygenated hemoglobin binds CO2 better; oxygenation releases it into the blood) and worsening ventilation-perfusion (V/Q) mismatch (reversal of hypoxic pulmonary vasoconstriction). Although his current PaCO2 is 48 mmHg (lower than baseline), maintaining a high PaO2 is not optimal management and predisposes him to instability or discharge on inappropriate amounts of oxygen. The goal is to titrate oxygen to the lowest effective dose.\n    \n2.  Acid-Base Status: The pH is 7.36, which is normal. The PaCO2 is 48 mmHg. Using the Henderson-Hasselbalch equation (or clinical estimation), the bicarbonate level is likely around 26-27 mEq/L. Since the pH is normal and not alkalemic, there is no \"post-hypercapnic metabolic alkalosis.\" Therefore, acetazolamide (Option E) is not indicated. Acetazolamide is used to treat metabolic alkalosis (usually pH > 7.45) to stimulate respiratory drive and facilitate weaning; in a patient with pH 7.36, it would cause metabolic acidosis and potentially increase the work of breathing dangerously.\n\n3.  Management: The most appropriate step is to reduce the supplemental oxygen to reach the target range for COPD (PaO2 roughly 60 mmHg, or SpO2 88-92%). This avoids the risks of hyperoxia and helps determine if the patient requires long-term oxygen therapy (LTOT) at discharge (indicated if PaO2 ≤ 55 mmHg, or 56-59 with complications).\n\n*   Option A: Correctly suggests weaning oxygen to a target PaO2 of 55-60 mmHg (corresponding to SpO2 ~88-90%), which is the safe target range for a CO2 retainer.\n*   Option B: Continuing the current high oxygen level is inappropriate.\n*   Option C: Increasing oxygen is incorrect.\n*   Option D: Unnecessary; arterial values are known.\n*   Option E: Incorrect as discussed (no metabolic alkalosis).\n\nThe answer is (A)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-002", "question": "A 45-year-old woman with a history of recurrent calcium oxalate kidney stones presents with acute pancreatitis. Lipase is 1200 U/L, calcium 11.8 mg/dL, PTH 85 pg/mL (normal 10-65). She is not on lithium or thiazides. A pancreatic protocol CT shows diffuse gland enlargement but no necrosis or ductal dilation. The most likely underlying etiology of her pancreatitis is:", "options": ["Primary hyperparathyroidism due to parathyroid adenoma", "Autoimmune pancreatitis (IgG4-related disease)", "Hereditary pancreatitis due to PRSS1 mutation", "Hypertriglyceridemia-induced pancreatitis", "Pancreatitis secondary to a gastrinoma (Zollinger-Ellison syndrome)"], "answer": "A", "answer_index": 0, "explanation": "The triad of hypercalcemia, elevated PTH, and recurrent calcium oxalate stones is classic for primary hyperparathyroidism. Hypercalcemia is a known, though uncommon, cause of pancreatitis. The elevated PTH confirms primary hyperparathyroidism, not secondary causes. While hypertriglyceridemia (D) can cause pancreatitis, it doesn't explain the hypercalcemia and elevated PTH. Gastrinoma (E) is associated with ulcers and diarrhea, not typically hypercalcemia and stones.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The clinical presentation and laboratory values are diagnostic of primary hyperparathyroidism (PHPT).\n\n1.  Hypercalcemia and Elevated PTH: The patient has hypercalcemia (calcium 11.8 mg/dL) with an inappropriately elevated parathyroid hormone (PTH 85 pg/mL). In the absence of lithium or thiazide use, this biochemical profile is the hallmark of primary hyperparathyroidism.\n2.  Kidney Stones: The history of recurrent calcium oxalate kidney stones is a classic clinical manifestation of PHPT due to chronic hypercalciuria.\n3.  Pancreatitis: Hypercalcemia is a well-established, though relatively uncommon, metabolic cause of acute pancreatitis. The proposed mechanism involves hypercalcemia leading to the deposition of calcium in the pancreatic duct and calcium-mediated activation of trypsinogen to trypsin within the pancreatic parenchyma, causing autodigestion and inflammation.\n4.  CT Findings: Diffuse gland enlargement is consistent with interstitial edematous pancreatitis, the inflammation resulting from the metabolic insult.\n\nLet's evaluate the other options:\n*   Autoimmune pancreatitis (B): While the \"sausage-shaped\" diffuse enlargement can be seen in AIP, AIP does not cause hypercalcemia or elevated PTH.\n*   Hereditary pancreatitis (C): Typically presents at a younger age and is not associated with hypercalcemia or high PTH.\n*   Hypertriglyceridemia (D): A cause of pancreatitis, but it does not result in hypercalcemia or elevated PTH.\n*   Gastrinoma (E): While MEN1 syndrome involves parathyroid adenomas (PHPT) and pancreatic neuroendocrine tumors (like gastrinomas), the direct cause of pancreatitis in this vignette is the metabolic derangement (hypercalcemia) from the parathyroid pathology. A gastrinoma itself primarily causes peptic ulcer disease (Zollinger-Ellison syndrome), which is not described here.\n\nTherefore, the single best answer explaining the combination of recurrent stones, hypercalcemia, elevated PTH, and pancreatitis is primary hyperparathyroidism.\n\nThe answer is (A)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-003", "question": "A 32-year-old woman presents with 3 weeks of progressive dyspnea and fatigue. Echocardiogram shows a large pericardial effusion with diastolic right atrial and right ventricular collapse. Right heart catheterization reveals equalization of diastolic pressures (RA 18, RV 18, PA 18/20, PCWP 18 mmHg). After pericardiocentesis of 800 mL of serosanguinous fluid, hemodynamics improve. Cytology is negative. Two days later, she develops recurrent dyspnea. Repeat echo shows reaccumulation of the effusion. The most appropriate definitive management is:", "options": ["Repeat pericardiocentesis and initiate colchicine", "Surgical creation of a pericardial window via subxiphoid approach", "Initiation of high-dose prednisone for suspected autoimmune pericarditis", "Pericardiectomy via left thoracotomy", "Intrapericardial instillation of bleomycin"], "answer": "B", "answer_index": 1, "explanation": "Recurrent symptomatic pericardial effusion with tamponade physiology, especially when cytology is negative (ruling out malignancy requiring specific therapy), is a clear indication for a definitive surgical procedure to prevent reaccumulation. A surgical pericardial window (subxiphoid or video-assisted) allows for drainage and biopsy. Pericardiectomy (D) is reserved for constrictive pericarditis. Steroids (C) are for inflammatory causes but are not definitive for recurrent effusion. Intrapericardial chemotherapy (E) is for malignant effusions.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient presents with recurrent cardiac tamponade despite initial pericardiocentesis. The key features are the rapid reaccumulation of fluid (within 2 days) and the serosanguinous nature of the fluid with negative cytology.\n\n1.  Diagnosis: The patient has a recurrent, symptomatic pericardial effusion causing tamponade physiology.\n2.  Management of Recurrence: Simple pericardiocentesis (Option A) has already failed to provide lasting resolution, evidenced by the rapid reaccumulation. Repeating it is unlikely to be definitive.\n3.  Surgical Options:\n    *   Pericardial Window (Option B): This is the most appropriate next step for recurrent pericardial effusions causing tamponade. A subxiphoid pericardial window creates a communication between the pericardial space and the pleural or peritoneal cavity (or subcutaneous tissue), allowing for continuous drainage and preventing pressure buildup. Crucially, it also allows for a pericardial biopsy, which has a higher diagnostic yield than fluid cytology alone, especially given the serosanguinous fluid which raises concern for malignancy or tuberculosis despite the initial negative cytology.\n    *   Pericardiectomy (Option D): Complete removal of the pericardium is a more extensive procedure with higher morbidity and mortality. It is typically reserved for constrictive pericarditis or cases of effusion refractory to less invasive surgical management (like a window). It is not the initial choice for a recurrent effusion.\n4.  Medical Management:\n    *   Prednisone (Option C): High-dose steroids are used for recurrent inflammatory pericarditis. However, initiating them without a definitive diagnosis or securing safe hemodynamics via drainage is inappropriate, especially given the life-threatening nature of tamponade.\n    *   Bleomycin (Option E): Intrapericardial sclerosis is an option for malignant effusions to prevent recurrence. However, the diagnosis of malignancy has not been established (cytology negative), and a window is generally preferred to secure drainage and obtain a biopsy first.\n\nTherefore, a surgical pericardial window is the standard of care for recurrent symptomatic pericardial effusion to provide definitive drainage and diagnostic tissue.\n\nThe answer is (B)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-004", "question": "A 70-year-old man with atrial fibrillation on apixaban (non-valvular) presents with acute onset of right-sided weakness and aphasia 4 hours after symptom onset. NIHSS is 15. CT head shows no hemorrhage. He is not a candidate for IV tPA due to anticoagulation. CT angiography shows a left M1 MCA occlusion. The most appropriate acute intervention is:", "options": ["Administer IV tPA after checking an INR and anti-Xa level", "Proceed directly to mechanical thrombectomy without thrombolysis", "Administer IV protamine to reverse apixaban, then give IV tPA", "Administer andexanet alfa, then give IV tPA", "Initiate IV heparin drip and observe for neurological improvement"], "answer": "B", "answer_index": 1, "explanation": "For patients with acute ischemic stroke and large vessel occlusion (LVO) who are not candidates for IV tPA, mechanical thrombectomy is the standard of care if performed within 24 hours of last known well and meeting other criteria (like NIHSS ≥6). Direct thrombectomy is non-inferior to bridging therapy (tPA + thrombectomy). Reversing anticoagulation to give tPA (C, D) delays definitive therapy and adds bleeding risk. Giving tPA on top of therapeutic anticoagulation (A) is contraindicated.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Here is the step-by-step reasoning for the correct answer:\n\n1.  Patient Status: The patient is presenting with a severe acute ischemic stroke (NIHSS 15) caused by a Large Vessel Occlusion (LVO) of the left M1 Middle Cerebral Artery (MCA). He is within the 6-hour time window for standard endovascular intervention (4 hours from onset).\n2.  Contraindication to IV tPA: The patient is on apixaban (a direct Factor Xa inhibitor). Current guidelines (AHA/ASA) state that IV alteplase (tPA) is generally contraindicated in patients who have received a dose of a direct oral anticoagulant (DOAC) such as apixaban within the last 48 hours, unless laboratory tests (specifically anti-Xa activity for apixaban) show normal coagulation activity. The prompt explicitly states he is not a candidate for IV tPA due to this anticoagulation.\n3.  Evaluating Option A: While checking anti-Xa levels is theoretically possible, the prompt states he is not a candidate. Furthermore, standard INR is not a reliable measure for apixaban effect. Delaying definitive treatment for labs when immediate mechanical intervention is indicated is not the best strategy.\n4.  Evaluating Option C and D: Option C suggests Protamine, which reverses heparin, not apixaban. Option D suggests using Andexanet alfa (a reversal agent for apixaban) followed by tPA. Current guidelines specifically advise *against* administering reversal agents to facilitate IV tPA administration due to the unknown safety profile and potential for pro-thrombotic complications.\n5.  Evaluating Option E: Heparin is not the standard acute treatment for ischemic stroke and does not re-open large vessel occlusions.\n6.  Evaluating Option B: Mechanical thrombectomy is the standard of care for patients with Large Vessel Occlusion (LVO) in the anterior circulation within 6 hours of symptom onset. In patients who are contraindicated for IV tPA (e.g., due to therapeutic anticoagulation), guidelines recommend proceeding directly to mechanical thrombectomy. This avoids the bleeding risks associated with tPA and the complexities/risks of reversal agents, while directly addressing the clot.\n\nThe answer is (B)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-005", "question": "A 55-year-old man with alcoholic cirrhosis (Child-Pugh B) is admitted with hepatic encephalopathy. He is started on lactulose. On day 3, he develops acute kidney injury. Serum sodium is 122 mEq/L (down from 128 on admission), creatinine 2.4 mg/dL (baseline 0.9), and he is clinically envolemic. Urine sodium is <10 mEq/L, urine osmolality 550 mOsm/kg. The most likely cause of his hyponatremia is:", "options": ["Syndrome of inappropriate antidiuretic hormone secretion (SIADH)", "Acute tubular necrosis from sepsis", "Hepatorenal syndrome type 1", "Pseudohyponatremia from hypertriglyceridemia", "Hyponatremia due to lactulose-induced diarrhea"], "answer": "E", "answer_index": 4, "explanation": "Lactulose causes an osmotic diarrhea, leading to loss of sodium and water, but relatively more water loss, resulting in hypertonic hyponatremia. The clinical picture (envolemic, high urine osmolality, low urine sodium) is consistent with volume depletion from GI losses, not SIADH (which has inappropriately high urine sodium). Hepatorenal syndrome (C) is characterized by low urine sodium but typically occurs in the setting of avid sodium retention and ascites, not acute diarrhea. ATN (B) would have high urine sodium.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "Here is a step-by-step analysis of the clinical scenario:\n\n1.  Patient's Baseline: The patient has Child-Pugh B alcoholic cirrhosis and was admitted for hepatic encephalopathy (HE).\n2.  Intervention: He was treated with lactulose. Lactulose is an osmotic laxative used to clear ammonia in HE by inducing frequent loose stools (diarrhea).\n3.  New Problem: On day 3, he develops Acute Kidney Injury (creatinine rose from 0.9 to 2.4 mg/dL) and worsening hyponatremia (sodium dropped from 128 to 122 mEq/L).\n4.  Urine Indices:\n    *   Urine Sodium < 10 mEq/L: This indicates avid renal sodium retention, which is the hallmark of a \"prerenal\" state or underfilling of the effective arterial blood volume. The kidneys are functioning structurally to conserve sodium. This findings rules out intrinsic renal disease (like ATN) and SIADH (where urine sodium is typically > 20–40 mEq/L due to volume expansion).\n    *   Urine Osmolality 550 mOsm/kg: The urine is concentrated, indicating significant Anti-Diuretic Hormone (ADH/vasopressin) activity.\n\nEvaluating the Options:\n\n*   A. SIADH: Incorrect. Diagnostic criteria for SIADH generally requires increased urine sodium (>40 mEq/L) and clinical euvolemia. In cirrhosis, the \"hypovolemia\" results from vasodilation and low effective arterial blood volume, which appropriately triggers ADH (as opposed to *inappropriate* secretion). The very low urine sodium (<10) rules out SIADH.\n*   B. ATN from sepsis: Incorrect. In ATN, the tubules are damaged and cannot reabsorb sodium or concentrate urine effectively. Urine sodium would be high (>40 mEq/L) and urine osmolality would be close to serum (isosthenuria, ~300 mOsm/kg). The labs here show intact tubular function.\n*   C. Hepatorenal syndrome type 1 (HRS-AKI): By definition, HRS is a diagnosis of exclusion. It can only be diagnosed in a patient with cirrhosis and AKI after intrinsic causes are ruled out and the kidney function does not improve after withdrawal of diuretics and volume expansion with albumin for 2 days. Because this patient has a clear precipitant (lactulose-induced volume depletion) that has not yet been treated/ruled out as the cause, diagnosing HRS is premature and likely incorrect.\n*   D. Pseudohyponatremia: Incorrect. There is no evidence of severe hypertriglyceridemia or paraproteinemia provided.\n*   E. Hyponatremia due to lactulose-induced diarrhea: Correct. Although lactulose causes osmotic water loss (which can lead to hypernatremia if water intake is restricted), in cirrhotic patients, the volume depletion caused by over-diuresis or diarrhea leads to a profound reduction in effective arterial blood volume. This triggers a massive non-osmotic release of ADH (vasopressin). If the patient has any free water intake (oral or IV), the kidney will avidly retain that water due to the high ADH, leading to worsening hyponatremia. The clinical picture of AKI with \"prerenal\" urine indices (Na < 10) in the setting of recent lactulose use is a classic presentation of volume depletion.\n\nThe answer is (E)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-006", "question": "A 28-year-old pregnant woman at 32 weeks gestation is admitted for severe preeclampsia with BP 170/110 mmHg. She is started on IV magnesium sulfate for seizure prophylaxis and IV labetalol for blood pressure control. One hour after initiation of magnesium, she becomes somnolent, with loss of deep tendon reflexes. Respiratory rate is 8 breaths/min. Serum magnesium level is 9.2 mg/dL. After securing the airway, the most specific immediate treatment is:", "options": ["IV administration of 10% calcium gluconate 1 gram over 10 minutes", "IV administration of furosemide 40 mg to enhance renal excretion", "Immediate hemodialysis", "Discontinuation of magnesium sulfate and administration of IV levothyroxine", "IV administration of pyridostigmine 2 mg"], "answer": "A", "answer_index": 0, "explanation": "Calcium gluconate is the direct antagonist to the life-threatening cardiac and neuromuscular effects of hypermagnesemia. It stabilizes cardiac membranes and reverses respiratory depression caused by magnesium. Furosemide (B) promotes excretion but is not immediate. Dialysis (C) is for severe cases with renal failure but is not the first step after airway management. Pyridostigmine (E) is for myasthenia, not magnesium toxicity.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Here is the step-by-step analysis to arrive at the correct answer:\n\n1.  Diagnosis: The patient is presenting with classic signs of magnesium toxicity following the administration of magnesium sulfate for preeclampsia. Her symptoms include somnolence, loss of deep tendon reflexes (patellar reflex is usually the first to disappear around 8–10 mg/dL), and respiratory depression (respiratory rate < 12 breaths/min). Her serum magnesium level is confirmed at 9.2 mg/dL, which is above the therapeutic range (4–7 mg/dL) and within the toxic range.\n\n2.  Pathophysiology: Magnesium acts as a calcium antagonist. High levels of magnesium block neuromuscular transmission by inhibiting the release of acetylcholine at the neuromuscular junction and interfering with calcium entry into cells. This leads to muscle weakness (loss of reflexes) and respiratory paralysis. It also affects cardiac conduction.\n\n3.  Treatment Priorities:\n    *   Stop the Magnesium: The first step is to discontinue the infusion (though this is not the specific *antidote* requested by the question, it is a necessary action).\n    *   Supportive Care: Airway and ventilation support are critical (the prompt states the airway is secured).\n    *   Specific Antidote: The physiological antagonist of magnesium is calcium. Calcium competes with magnesium at the neuromuscular junction and can temporarily reverse the neuromuscular blockade and respiratory depression, as well as protect the heart.\n\n4.  Evaluating the Options:\n    *   A. IV administration of 10% calcium gluconate 1 gram over 10 minutes: This is the correct specific treatment. Calcium gluconate (or calcium chloride) provides intravenous calcium to antagonize the effects of magnesium. 1 gram corresponds to 10 mL of a 10% solution, usually given slowly to avoid arrhythmias.\n    *   *B. IV administration of furosemide*: While diuretics and IV fluids can help excrete magnesium, this is a slower process and is not the immediate antidote for life-threatening respiratory depression or cardiac issues.\n    *   *C. Immediate hemodialysis*: This is reserved for patients with severe renal failure or massive overdose who do not respond to calcium and fluids. It is not the *immediate* first-line specific medication.\n    *   *D. Levothyroxine*: This is a thyroid hormone replacement and has no role in treating magnesium toxicity.\n    *   *E. Pyridostigmine*: This is an acetylcholinesterase inhibitor used in myasthenia gravis. While magnesium toxicity mimics a neuromuscular blockade, the specific direct antagonist is calcium.\n\nThe answer is (A)\n\nThe answer is (A)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-007", "question": "A 62-year-old man with a history of asbestos exposure 30 years ago presents with unilateral right-sided pleural effusion. Thoracentesis reveals exudative fluid (by Light's criteria) with cytology positive for adenocarcinoma. PET-CT shows FDG-avid right pleural thickening and effusion, with no other distant metastases. The next best step in management is:", "options": ["Systemic chemotherapy with platinum-pemetrexed", "Pleurodesis followed by systemic chemotherapy", "Extrapleural pneumonectomy", "Pleurectomy/decortication followed by adjuvant chemoradiation", "Immunotherapy with pembrolizumab as first-line treatment"], "answer": "D", "answer_index": 3, "explanation": "This describes a likely diagnosis of malignant pleural mesothelioma (given asbestos exposure, unilateral effusion, pleural thickening). For resectable disease (stage I-III) in a fit patient, the standard of care is maximal cytoreductive surgery (pleurectomy/decortication) followed by adjuvant chemotherapy and possibly radiation. Extrapleural pneumonectomy (C) is a more radical, less commonly performed option. Systemic therapy alone (A) is for unresectable disease. Pleurodesis (B) is palliative.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient is a 62-year-old man with a history of asbestos exposure, presenting with a pleural effusion and pleural thickening. Although asbestos exposure and pleural thickening are classic signs of malignant pleural mesothelioma (MPM), the key information provided is the cytology result: positive for adenocarcinoma.\n\n1.  Diagnosis: The diagnosis is Stage IV Non-Small Cell Lung Cancer (NSCLC), specifically adenocarcinoma, with malignant pleural effusion (M1a disease). Note that while mesothelioma is associated with asbestos, asbestos exposure actually confers a higher risk of developing lung cancer (adenocarcinoma or squamous cell carcinoma) than mesothelioma. Furthermore, mesothelioma cytology is distinct and would not be labeled \"adenocarcinoma\" (which implies glandular formation and mucin production/TTF-1 positivity). Pseudomesotheliomatous adenocarcinoma is a form of lung cancer that mimics mesothelioma clinically but is treated as advanced lung cancer.\n\n2.  Management:\n    *   Surgery (Options C and D): Surgical resection (Extrapleural pneumonectomy or Pleurectomy/decortication) is contraindicated for Stage IV NSCLC with malignant pleural effusion. There is no survival benefit, and it adds significant morbidity. These options are typically reserved for select cases of mesothelioma, not metastatic adenocarcinoma.\n    *   Option E (Immunotherapy): Pembrolizumab monotherapy is indicated for NSCLC with PD-L1 expression $\\ge$ 1% (or $\\ge$ 50% depending on the setting) or in combination with chemotherapy. Without information regarding PD-L1 status or driver mutations (EGFR, ALK), choosing pembrolizumab *alone* as the next step is not the definitive standard for all comers compared to chemotherapy or chemo-immunotherapy combinations.\n    *   Option B (Pleurodesis): While pleurodesis manages the symptom of effusion, it does not treat the underlying malignancy. In chemo-sensitive tumors (or moderately sensitive like adenocarcinoma), systemic treatment is the primary management. Pleurodesis is reserved for recurrent, symptomatic effusions where the lung is expandable. The \"next best step\" focuses on treating the cancer.\n    *   Option A (Systemic Chemotherapy): The standard chemotherapy regimen for non-squamous NSCLC (adenocarcinoma) is a Platinum doublet containing Pemetrexed (e.g., Cisplatin/Pemetrexed or Carboplatin/Pemetrexed). Pemetrexed is an antifolate that is effective in non-squamous histology. Interestingly, this regimen is *also* the standard first-line chemotherapy for malignant pleural mesothelioma. Therefore, regardless of whether a student incorrectly identifies this as mesothelioma or correctly as adenocarcinoma, this regimen is the pharmacologically correct choice. Given the diagnosis of adenocarcinoma, this is the appropriate systemic palliative treatment.\n\nThe answer is (A)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-008", "question": "A 40-year-old woman presents with palpitations, heat intolerance, and weight loss. TSH is <0.01 mIU/L, free T4 is 3.2 ng/dL (high). Thyroid ultrasound shows a 2 cm hypoechoic nodule in the right lobe. Radioactive iodine uptake scan shows diffusely increased uptake (45% at 24 hours) with a photopenic area corresponding to the nodule. The most likely diagnosis is:", "options": ["Graves' disease with a coexisting cold nodule", "Toxic multinodular goiter", "Subacute thyroiditis", "Factitious thyrotoxicosis", "Marine-Lenhart syndrome (Graves' disease with a functioning nodule)"], "answer": "A", "answer_index": 0, "explanation": "The diffusely increased uptake is diagnostic of Graves' disease. The photopenic ('cold') nodule within an area of diffusely high uptake indicates a non-functioning nodule, which raises concern for malignancy and requires FNA biopsy. Marine-Lenhart syndrome (E) is Graves' with a *functioning* (hot) nodule. Toxic MNG (B) would show multiple areas of increased uptake. Subacute thyroiditis (C) shows very low uptake.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The clinical presentation and laboratory results (suppressed TSH, elevated free T4) indicate primary hyperthyroidism. The radioactive iodine uptake (RAIU) scan provides the etiology:\n\n1.  Diffusely increased uptake (45%): This is the hallmark pattern of Graves' disease, caused by thyroid-stimulating immunoglobulins stimulating the entire gland.\n2.  Photopenic area regarding the nodule: \"Photopenic\" means the area is not taking up the radioactive iodine, indicating a \"cold\" or non-functioning nodule.\n\nTherefore, the patient has Graves' disease (causing the diffuse uptake and thyrotoxicosis) with a coexisting cold nodule.\n\n*   Option B (Toxic multinodular goiter) typically shows a patchy uptake pattern with multiple hot spots, not the diffuse uptake typical of Graves', and the background tissue is often suppressed.\n*   Option C (Subacute thyroiditis) presents with a painful thyroid and a very low (near zero) RAIU because the gland is leaking hormone rather than synthesizing it.\n*   Option D (Factitious thyrotoxicosis) involves exogenous hormone intake, which suppresses the thyroid gland, resulting in a very low RAIU.\n*   Option E (Marine-Lenhart syndrome) describes Graves' disease coexisting with *functioning* (hot or warm) nodules. Since the nodule in this case is photopenic (cold), this diagnosis is incorrect.\n\nThe co-occurrence of a cold nodule in the setting of Graves' disease is a specific clinical scenario (Option A) that warrants fine-needle aspiration (FNA) due to a potentially higher risk of malignancy in the cold nodule compared to other settings.\n\nThe answer is (A)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-009", "question": "A 50-year-old man with diabetes mellitus and hypertension is found to have a serum potassium of 6.8 mEq/L on routine labs. He is asymptomatic. ECG shows peaked T waves. He is given IV calcium gluconate, insulin/dextrose, and albuterol. His potassium decreases to 6.0 mEq/L. Renal function is normal. Further workup reveals a low serum aldosterone and elevated plasma renin activity. The most likely cause of his hyperkalemia is:", "options": ["Type 4 renal tubular acidosis (hyporeninemic hypoaldosteronism)", "Addison's disease", "Gordon's syndrome (pseudohypoaldosteronism type II)", "Spironolactone use", "Rhabdomyolysis"], "answer": "C", "answer_index": 2, "explanation": "Gordon's syndrome (familial hyperkalemic hypertension) is characterized by hyperkalemia, hypertension, normal GFR, metabolic acidosis, and *suppressed* renin but *normal or high* aldosterone. The key here is the elevated renin, which rules out hyporeninemic hypoaldosteronism (A, which has low renin and low aldosterone) and points to a primary renal defect in potassium excretion. Addison's (B) has low aldosterone and high renin but also has hyponatremia and hypotension.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The clinical presentation is a 50-year-old man with diabetes, hypertension, and significant hyperkalemia (6.8 mEq/L). The workup reveals a low serum aldosterone and elevated plasma renin activity.\n\nLet's analyze the options based on the renin-aldosterone profile:\n\n1.  A. Type 4 renal tubular acidosis (hyporeninemic hypoaldosteronism): This condition is commonly associated with diabetic nephropathy. The pathophysiology involves damage to the juxtaglomerular apparatus, leading to defective renin secretion. Consequently, patients have low renin and low aldosterone. The option explicitly states \"hyporeninemic,\" which contradicts the patient's \"elevated plasma renin activity.\" Therefore, this is incorrect.\n\n2.  B. Addison's disease (Primary Adrenal Insufficiency): In primary adrenal insufficiency, there is destruction of the adrenal cortex, leading to an inability to produce aldosterone (and cortisol). The resulting hypoaldosteronism causes renal sodium wasting and potassium retention (hyperkalemia). The loss of sodium and volume stimulates the release of renin. Thus, the classic profile is high renin and low aldosterone. This matches the patient's lab results perfectly. Although the patient has a history of hypertension (which is usually associated with volume overload or vasoconstriction), Addison's disease can occur in patients with pre-existing essential hypertension or autoimmune conditions (like Type 1 diabetes in Polyglandular Autoimmune Syndrome Type 2). The lab profile is the decisive factor here.\n\n3.  C. Gordon's syndrome (Pseudohypoaldosteronism Type II): This is caused by a genetic defect leading to increased sodium chloride reabsorption in the distal tubule (overactive thiazide-sensitive cotransporter). Patients develop hypertension and volume expansion, which suppresses renin and aldosterone. The profile is low renin and low (or normal) aldosterone. This does not match the patient's high renin.\n\n4.  D. Spironolactone use: Spironolactone is a mineralocorticoid receptor antagonist. It blocks aldosterone's effect on the kidney. The body perceives a state of aldosterone deficiency (salt wasting), which stimulates the RAAS pathway. This leads to high renin and high aldosterone levels (as the adrenal gland attempts to overcome the blockade). The patient has low aldosterone, making this incorrect.\n\n5.  E. Rhabdomyolysis: This causes hyperkalemia due to the release of intracellular potassium. It does not cause a primary defect in the RAAS axis characterized by low aldosterone and high renin. Typically, hyperkalemia directly stimulates aldosterone secretion, so aldosterone levels would be normal or high.\n\nConclusion: The only option that fits the specific biochemical profile of Low Aldosterone and Elevated Renin is Addison's disease. This pattern indicates a primary defect in the adrenal gland's ability to secrete aldosterone despite appropriate stimulation by renin/angiotensin.\n\nThe answer is (B)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-010", "question": "A 65-year-old man with a mechanical aortic valve (On-X) on warfarin presents with a transient ischemic attack. INR on presentation is 1.8 (target 2.5-3.5). He has no bleeding history. The most appropriate adjustment to his antithrombotic regimen is:", "options": ["Increase warfarin dose to achieve INR 2.5-3.5; add aspirin 81 mg daily", "Increase warfarin dose to achieve INR 2.5-3.5; no aspirin needed", "Switch to apixaban 5 mg twice daily", "Add clopidogrel 75 mg daily to current warfarin therapy", "Discontinue warfarin and initiate dual antiplatelet therapy with aspirin and clopidogrel"], "answer": "A", "answer_index": 0, "explanation": "For a mechanical aortic valve, the standard of care is warfarin with a target INR of 2.5-3.5. In patients who have a thromboembolic event despite therapeutic INR, adding aspirin 75-100 mg is recommended. Since his INR was subtherapeutic at the time of the TIA, the first step is to optimize INR control. However, given the event, adding low-dose aspirin is now indicated based on PROACT and other trials. Direct oral anticoagulants (C) are contraindicated in mechanical valves. Dual antiplatelet therapy (E) is inferior to warfarin for valve protection.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Based on the 2020 ACC/AHA Guidelines for the Management of Patients With Valvular Heart Disease, patients with a mechanical prosthetic valve should generally receive aspirin 75 to 100 mg daily in addition to vitamin K antagonist (VKA) therapy (Class 1 Recommendation), provided there are no contraindications (such as a history of major bleeding).\n\nIn this scenario, the patient has a mechanical aortic valve and presents with a thromboembolic event (TIA). His INR is 1.8, which is subtherapeutic compared to the stated target of 2.5–3.5.\n\n1.  INR Management: The primary cause of the TIA is likely the subtherapeutic anticoagulation. Therefore, the warfarin dose must be increased to achieve the therapeutic range. For a patient with a mechanical AVR and a thromboembolic event, the target INR is typically increased to 3.0 (range 2.5–3.5), which matches the target given in the prompt.\n2.  Antiplatelet Therapy: Guidelines recommend adding low-dose aspirin (75–100 mg) to VKA for all patients with mechanical valves to reduce the risk of ischemic events, especially in those who have already suffered an embolic event. The specific mention of the On-X valve is notable because this valve was FDA approved for a lower INR target (1.5–2.0) *only if combined with aspirin*. However, even with standard INR targets, aspirin is recommended. Since this patient has no history of bleeding, adding aspirin is the appropriate evidence-based focused adjustment.\n\nWhy other options are incorrect:\n*   B: While correcting the INR is essential, explicitly identifying that \"no aspirin is needed\" contradicts Class 1 guideline recommendations for mechanical valves.\n*   C: Direct oral anticoagulants (DOACs) like apixaban are contraindicated in patients with mechanical heart valves due to increased rates of thromboembolism and bleeding (proven in the RE-ALIGN trial for dabigatran, and applicable to factor Xa inhibitors).\n*   D: Maintaining the current warfarin dose is inappropriate because the patient is subtherapeutic. Clopidogrel is not the first-line antiplatelet add-on for mechanical valves unless aspirin is contraindicated.\n*   E: Discontinuing warfarin for dual antiplatelet therapy is unsafe and would carry a very high risk of valve thrombosis and stroke.\n\nThe answer is (A)"}]